Insider Selling: Charles River Laboratories International (NYSE:CRL) Director Sells $7,901,575.00 in Stock

Charles River Laboratories International, Inc. (NYSE:CRL) Director James Foster sold 28,733 shares of the business’s stock in a transaction dated Monday, August 10th. The stock was sold at an average price of $275.00, for a total transaction of $7,901,575.00. Following the sale, the director directly owned 31,596 shares of the company’s stock, valued at approximately $8,688,900. The trade was a 47.63% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Charles River Laboratories International Stock Up 1.7%

NYSE CRL traded up $4.70 during trading hours on Tuesday, hitting $281.70. The company’s stock had a trading volume of 1,180,097 shares, compared to its average volume of 926,631. Charles River Laboratories International, Inc. has a 52 week low of $144.26 and a 52 week high of $282.39. The company has a market capitalization of $13.45 billion, a PE ratio of -58.08, a price-to-earnings-growth ratio of 2.77 and a beta of 1.38. The company has a current ratio of 1.35, a quick ratio of 1.04 and a debt-to-equity ratio of 0.92. The company’s 50-day simple moving average is $216.74 and its two-hundred day simple moving average is $189.45.

Charles River Laboratories International (NYSE:CRL) last issued its quarterly earnings data on Wednesday, August 5th. The medical research company reported $3.02 EPS for the quarter, topping analysts’ consensus estimates of $2.77 by $0.25. The firm had revenue of $1 billion during the quarter, compared to analyst estimates of $980.53 million. Charles River Laboratories International had a positive return on equity of 15.75% and a negative net margin of 5.96%.The company’s revenue for the quarter was down 2.7% on a year-over-year basis. During the same period in the previous year, the company posted $3.12 EPS. Charles River Laboratories International has set its FY 2026 guidance at 11.150-11.450 EPS. Research analysts anticipate that Charles River Laboratories International, Inc. will post 11.35 EPS for the current fiscal year.

More Charles River Laboratories International News

Here are the key news stories impacting Charles River Laboratories International this week:

• Positive Sentiment: Analyst outlook remains broadly favorable. Piper Sandler set a $300 price target, while Barclays maintained an “overweight” rating with the same target and RBC raised its objective to $282 while rating CRL “outperform.” Overall, 12 analysts rate the stock a Buy, three rate it Hold and one rates it Sell, producing a consensus “Moderate Buy” rating. Charles River Laboratories International Sets New 52-Week High
• Positive Sentiment: Recent quarterly results exceeded expectations. Charles River reported adjusted earnings of $3.02 per share versus the $2.77 consensus estimate, while revenue of approximately $1 billion topped expectations of $980.5 million. Fiscal 2026 earnings guidance remains $11.15–$11.45 per share, reinforcing the investment case despite uneven year-over-year results.
• Neutral Sentiment: International markets are a key focus for investors. A recent analysis examined changes in Charles River’s international revenue and how those trends could affect Wall Street forecasts and the stock’s future performance. International Markets and Charles River: A Deep Dive for Investors
• Negative Sentiment: Executive stock sales may weigh on sentiment. EVP Victoria Creamer sold 4,179 shares for approximately $1.08 million, reducing her position by 12.21%. Chief Accounting Officer Michael Gunnar Knell separately sold 6,645 shares worth about $1.73 million, cutting his holdings by 35.92%. These transactions are not necessarily negative fundamental signals, but they can raise caution after the stock’s strong rally.
• Negative Sentiment: Some fundamental risks remain. Quarterly revenue declined 2.7% year over year, earnings fell from $3.12 per share in the prior-year period, and the company reported a negative net margin. The consensus price target of $255.65 is also below recent trading levels, suggesting analysts may see limited near-term upside despite the positive ratings.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the business. Vanguard Group Inc. increased its holdings in Charles River Laboratories International by 0.8% during the fourth quarter. Vanguard Group Inc. now owns 5,887,175 shares of the medical research company’s stock worth $1,174,374,000 after buying an additional 47,432 shares during the last quarter. Eos Management L.P. bought a new stake in Charles River Laboratories International in the fourth quarter worth about $839,000. Assetmark Inc. boosted its stake in Charles River Laboratories International by 17.9% in the fourth quarter. Assetmark Inc. now owns 43,809 shares of the medical research company’s stock valued at $8,739,000 after acquiring an additional 6,666 shares during the last quarter. M&T Bank Corp grew its position in shares of Charles River Laboratories International by 1,424.9% during the 4th quarter. M&T Bank Corp now owns 27,997 shares of the medical research company’s stock valued at $5,585,000 after acquiring an additional 26,161 shares during the period. Finally, Avidity Partners Management LP bought a new position in shares of Charles River Laboratories International during the 1st quarter valued at approximately $1,670,000. Institutional investors own 98.91% of the company’s stock.

Analyst Ratings Changes

Several equities analysts have weighed in on CRL shares. Morgan Stanley raised their price objective on Charles River Laboratories International from $260.00 to $300.00 and gave the company an “overweight” rating in a research note on Friday. Barclays reiterated an “overweight” rating and issued a $300.00 target price on shares of Charles River Laboratories International in a report on Wednesday, August 5th. Evercore reissued an “outperform” rating on shares of Charles River Laboratories International in a research report on Wednesday, August 5th. Sanford C. Bernstein set a $250.00 price target on shares of Charles River Laboratories International in a report on Wednesday, July 1st. Finally, Robert W. Baird set a $291.00 price objective on shares of Charles River Laboratories International in a research note on Thursday, August 6th. Twelve research analysts have rated the stock with a Buy rating, three have given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, Charles River Laboratories International has a consensus rating of “Moderate Buy” and an average price target of $255.65.

About Charles River Laboratories International

Charles River Laboratories International, Inc is a leading provider of research models and preclinical and clinical support services for the pharmaceutical, biotechnology and medical device industries. The company’s core offerings include discovery, safety assessment, toxicology, and pathology services, as well as supply of laboratory animals and related diagnostics. Services extend across in vivo and in vitro testing, biologics testing, and support for advanced therapies, helping clients accelerate drug development from early discovery through regulatory submission.

Founded in 1947 in Wilmington, Massachusetts, Charles River has grown through strategic investments and acquisitions to establish a broad portfolio of capabilities.